These data demonstrated that fgl2 upregulated Fasn and SREBP-2, which contribute to lipogenesis, but downregulated PPARα and CPT1A, which enhance lipolysis, particularly in HFD-induced NASH. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatohepatitis.